Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus

Table 8

Summary of emerging lenalidomide combination therapies in the first- and second-line treatment of multiple myeloma.

Combination	First line		≥Second line
	Efficacy	Major toxicities	Efficacy	Major toxicities
MPR; Palumbo et al., 2007 [20]	81% ≥ PR	Hematological toxicity
MPR-R; Palumbo et al., 2010 [21]			75% ≥ PR	Hematological toxicity, infections
RMPT; Palumbo et al., 2010 [22]
RVD; Richardson et al., 2009, 2010 [23, 24]	100% ≥ PR	Hematological toxicity, sensory neuropathy	61% ≥ MR	Hematological toxicity
CPR; Reece et al., 2010 [25]			94% ≥ MR	Hematological toxicity
CRD; Schey et al., 2010 [26]			81% ≥ PR	Hematological toxicity
RVDC; Kumar et al., 2010 [27]	96% ≥ PR	Hematological toxicity, sensory neuropathy
CRd; Kumar et al., 2011 [28]	85% ≥ PR	Hematological; toxicity
RVDD; Jakubowiak et al., 2011 [29]	95% ≥ PR	Fatigue, constipation, sensory neuropathy, infection

MPR: melphalan, prednisone, lenalidomide; PR: partial response; MPR-R: MPR + lenalidomide maintenance until progression; RMPT: lenalidomide, melphalan, prednisone, thalidomide; RVD: lenalidomide, bortezomib, dexamethasone; MR: minimal response; CPR: cyclophosphamide, prednisone, lenalidomide; CRD: cyclophosphamide, lenalidomide, dexamethasone; RVDC: lenalidomide, bortezomib, dexamethasone, cyclophosphamide; CRd: cyclophosphamide, lenalidomide, dexamethasone; RVDD: lenalidomide, bortezomib, pegylated liposomal doxorubicin, dexamethasone.